Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer

Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumor suppressor p53. Our objective was to engender synthetic lethality to paclitaxel, the frontline treatment for endometrial cancer, in tumors with mutant p53 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebeid, Kareem, Meng, Xiangbing, Thiel, Kristina W, Do, Anh-Vu, Geary, Sean M, Morris, Angie S, Pham, Erica L, Wongrakpanich, Amaraporn, Chhonker, Yashpal S, Murry, Daryl J, Leslie, Kimberly K, Salem, Aliasger K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762267/
https://www.ncbi.nlm.nih.gov/pubmed/29203914
http://dx.doi.org/10.1038/s41565-017-0009-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762267/
https://www.ncbi.nlm.nih.gov/pubmed/29203914
http://dx.doi.org/10.1038/s41565-017-0009-7

Ejemplares similares